Wednesday, 9 February 2011

New version of EudraGMP allows access to information from all Member States

EudraGMP is the name for the Community database on manufacturing and import authorisations and Good Manufacturing Practice (GMP) certificates.

The European Medicines Agency has launched a new version of its EudraGMP database giving the general public access to information on manufacturing inspections performed by regulatory authorities from all European Economic Area (EEA) countries.

EudraGMP, which was first launched in May 2007, contains information on all manufacturers of human and veterinary medicines located in the EEA, and other manufacturers outside the EEA that have been inspected by European regulatory authorities. It includes details of the manufacturers' manufacturing and importation authorisations and good-manufacturing-practice (GMP) certificates.

The latest version of the database allows public access to the authorisation and GMP certificates coming from all countries in the EEA, including all European Union (EU) Member States plus Iceland, Liechtenstein and Norway. Previously, limited information coming from only some European countries was available to the public.

This initiative, which is part of the Agency's drive towards a greater level of openness and transparency, will
Improve the sharing of information between regulators and industry
Aid the co-ordination of activities related to manufacturing authorisations and GMP certificates between regulatory agencies in different European countries
Eliminate the need for industry to submit applications in paper form
Facilitate the sharing of information on the outcome of inspections in the EU with regulatory authorities elsewhere in the world.

The information in the database is continually updated by European regulatory authorities. The Agency expects around 3,000 new certificates to be imported into EudraGMP every year. It also expects the database to grow rapidly over the next few years, following the introduction of inspections in countries outside the EU and new GMP requirements for active gold


  1. HI Eric,

    I regularly follow ur blogs in CR. I have a situation where, my patient is blind, illiterate. How do I conduct informed consent process for this patient? Kindly respond.

  2. Hi, nice post. Well what can I say is that these is an interesting and very informative topic. Thanks for sharing your ideas, its not just entertaining but also gives your reader knowledge. Good blogs style too, Cheers!

    clinical research site